WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012114131) LECITHIN:CHOLESTEROL ACYLTRANSFERASE (LCAT) AND ITS ROLE IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/114131    International Application No.:    PCT/GR2011/000026
Publication Date: 30.08.2012 International Filing Date: 08.07.2011
IPC:
A61K 38/45 (2006.01), A61K 9/00 (2006.01), A61K 48/00 (2006.01), C12N 9/10 (2006.01), A61P 1/16 (2006.01), A61P 3/06 (2006.01)
Applicants: UNIVERSITY OF PATRAS [GR/GR]; Panepistimioupolis, Rio GR-26500 Patras (GR) (For All Designated States Except US).
KYPREOS, Kyriakos E. [GR/GR]; (GR).
PAPACHRISTOU, Dionysios J. [GR/GR]; (GR) (For US Only)
Inventors: KYPREOS, Kyriakos E.; (GR).
PAPACHRISTOU, Dionysios J.; (GR)
Agent: MALAMIS, Alkisti-Irene; 52 Skoufa str., GR-106 72 Athens (GR)
Priority Data:
20110100124 25.02.2011 GR
Title (EN) LECITHIN:CHOLESTEROL ACYLTRANSFERASE (LCAT) AND ITS ROLE IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
(FR) LÉCITHINE/CHOLESTÉROL ACYLTRANSFÉRASE (LCAT) ET SON RÔLE DANS LA STÉATOSE HÉPATIQUE NON ALCOOLIQUE (SHNA)
Abstract: front page image
(EN)Lecithin:cholesterol acyltransferase (LCAT) is responsible for the esterification of the free cholesterol of plasma lipoproteins. In the present invention, we describe the role of LCAT in hepatic triglyceride accumulation and the development of diet-induced nonalcoholic fatty liver disease (NAFLD). LCAT is described as a novel therapeutic agent for the treatment of NAFLD.
(FR)La lécithine/cholestérol acyltransférase (LCAT) est responsable de l'estérification du cholestérol libre des lipoprotéines plasmatiques. Dans la présente invention, nous décrivons le rôle de la LCAT dans l'accumulation de triglycérides hépatiques et le développement d'une stéatose hépatique non alcoolique (SHNA) induite par le régime alimentaire. La LCAT est décrite comme un nouvel agent thérapeutique pour le traitement de la SHNA.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)